A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

Paul K. Paik,Charles M. Rudin,Andrew Brown,Naiyer A. Rizvi,Naoko Takebe,William D. Travis,Leonard P. James,Michelle S. Ginsberg,Rosalyn A. Juergens,Susan Markus,Leslie Tyson,Sara Subzwari,Mark G. Kris,Lee M. Krug

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

2010

Paul K. Paik
Charles M. Rudin
Andrew Brown
Naiyer A. Rizvi
Naoko Takebe
William D. Travis
Leonard P. James
Michelle S. Ginsberg
Rosalyn A. Juergens
Susan Markus
Leslie Tyson
Sara Subzwari
Mark G. Kris
Lee M. Krug

Purpose To establish the safety, maximum tolerated dose (MTD), recommended phase II dose, and preliminary antitumor activity of obatoclax mesylate (GX15-070MS), a Bcl-2 antagonist, in combination with topotecan in patients with solid tumor malignancies.

Keywords:

Topoisomerase
Cancer
Antagonist
Pharmacology
Topotecan
Febrile neutropenia
Obatoclax
Enzyme inhibitor
Lung cancer
Medicine
Apoptosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations